Current hemostatic agents recommended for AHA
| . | Recombinant factor VII activated (rFVIIa) . | Activated prothrombin complex concentrate (aPCC) . | Recombinant porcine factor VIII (rpFVIII) . |
|---|---|---|---|
| Eptacog alfa, NovoSeven®RT | Anti-inhibitor coagulant complex, FEIBA® | Antihemophilic factor (recombinant), porcine sequence, Obizur® | |
| Indication | • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia30 | • Hemophilia A and B patients with inhibitors31 | • On-demand treatment and control of bleeding episodes in adults with acquired hemophilia A32 |
| Dosing | • 70-90 mcg/kg IV every 2-3 hours until hemostasis achieved30 | • 50-100 U/kg IV31 every 6-12 hours | • Initial dose 200 U/kg IV then titrate based on Factor VIII (FVIII) levels32 |
| Limitation of use | • Serious arterial and venous thrombotic events following administration have been reported30 | • Thromboembolic events reported during postmarketing surveillance, particularly following the administration of high doses and/or in patients with thrombotic risk factors31 • Contraindicated in acute thrombosis or embolism (including myocardial infarction)31 | • Safety and efficacy has not been established in patients with a baseline anti-porcine factor VIII inhibitor titer >20 BU32 |
| . | Recombinant factor VII activated (rFVIIa) . | Activated prothrombin complex concentrate (aPCC) . | Recombinant porcine factor VIII (rpFVIII) . |
|---|---|---|---|
| Eptacog alfa, NovoSeven®RT | Anti-inhibitor coagulant complex, FEIBA® | Antihemophilic factor (recombinant), porcine sequence, Obizur® | |
| Indication | • Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia30 | • Hemophilia A and B patients with inhibitors31 | • On-demand treatment and control of bleeding episodes in adults with acquired hemophilia A32 |
| Dosing | • 70-90 mcg/kg IV every 2-3 hours until hemostasis achieved30 | • 50-100 U/kg IV31 every 6-12 hours | • Initial dose 200 U/kg IV then titrate based on Factor VIII (FVIII) levels32 |
| Limitation of use | • Serious arterial and venous thrombotic events following administration have been reported30 | • Thromboembolic events reported during postmarketing surveillance, particularly following the administration of high doses and/or in patients with thrombotic risk factors31 • Contraindicated in acute thrombosis or embolism (including myocardial infarction)31 | • Safety and efficacy has not been established in patients with a baseline anti-porcine factor VIII inhibitor titer >20 BU32 |